Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL

Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL

Atezolizumab with venetoclax and obinutuzumab in patients with CLLПодробнее

Atezolizumab with venetoclax and obinutuzumab in patients with CLL

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCL

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023Подробнее

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023

Venetoclax and Obinutuzumab in CLLПодробнее

Venetoclax and Obinutuzumab in CLL

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZLПодробнее

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL

Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS ptsПодробнее

Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS pts

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?

Chronic Lymphocytic Leukemia Treatment & Side Effects (Venetoclax & Obinutuzumab) | Tamsin (3 of 3)Подробнее

Chronic Lymphocytic Leukemia Treatment & Side Effects (Venetoclax & Obinutuzumab) | Tamsin (3 of 3)

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLLПодробнее

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLLПодробнее

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

What is CLL, and does everyone really needs treatment? | Dr. Jeff Sharman | Oncology Brothers #2023Подробнее

What is CLL, and does everyone really needs treatment? | Dr. Jeff Sharman | Oncology Brothers #2023

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

Obinutuzumab + Venetoclax for Frontline CLL

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLLПодробнее

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLLПодробнее

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLL

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLLПодробнее

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL